CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

A New Era in Pain Management With COX-2 Specific Inhibitors CME
Faculty: Chairperson: Evan F. Ekman, MD; Faculty: Carl J. Basamania, MD, FACS; Scott D. Boden, MD
Disclosures

Release Date: May 21, 2002; Valid for credit through May 21, 2003

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "A New Era in Pain Management With COX-2 Specific Inhibitors" symposium held at the Adam's Mark Hotel in Dallas, Texas on February 14, 2002.

Contents of This CME Activity

Medscape Editorial Note, February 9, 2005

Since the writing of this content, certain published data analyses and public announcements have called into question the cardiovascular safety of some of the COX-2 inhibitors and standard NSAIDs. Results of such publications may have affected certain information contained in this article, causing it to be outdated or possibly inaccurate. In order to keep our members current on this important therapeutic area, Medscape is providing regularly updated information related to NSAIDs in the Medscape NSAID Alert Center. This center includes commentary, abstracts, and statements from the US Food and Drug Administration, National Institutes of Health, and other policy makers, as well as other articles that are intended to provide supplementary information for assessing the accuracy of this content.

This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Recent Trials Investigating the Efficacy of COX-2 Specific Inhibitors in Pain and Arthritis
    Introduction and Overview
    Orthopaedic Pain
    Effects of Pain
    Pathophysiology of Pain
    Complications With Non-Selective Anti-inflammatories
    Effects of Anti-inflammatories on Platelet Function
    Efficacy of COX-2 Specific Inhibitors: Rofecoxib
    Efficacy of COX-2 Specific Inhibitors: Celecoxib
    Efficacy of COX-2 Specific Inhibitors: Celecoxib in Post-Orthopaedic Pain
    Efficacy of COX-2 Specific Inhibitors: Celecoxib in Ankle Sprain
    Efficacy of COX-2 Specific Inhibitors: Celecoxib in Acute Pain
    Efficacy of COX-2 Specific Inhibitors: Valdecoxib
    Efficacy of COX-2 Specific Inhibitors: Valdecoxib for Pain
    Efficacy of COX-2 Specific Inhibitors: Valdecoxib for Surgery
    Efficacy of COX-2 Specific Inhibitors: Valdecoxib for Arthritis
    Efficacy of COX-2 Specific Inhibitors: Valdecoxib Conclusions
    Goals of Orthopaedic Pain Management

  2. Safety Profiles of COX-2 Specific Inhibitors: The Gastrointestinal Tract and Beyond, With Perspectives on Cardiorenal Effects
    Gastrointestinal Adverse Effects of Conventional Non-Steroidal Anti-inflammatory Drugs
    Gastrointestinal Tolerability of Therapy With COX-2 Specific Inhibitors: CLASS and VIGOR Trials
    Gastrointestinal Tolerability of Therapy With COX-2 Specific Inhibitors: SUCCESS I Trial
    Gastrointestinal Tolerability of Therapy With Newer COX-2 Specific Inhibitors
    Serious Gastrointestinal Outcomes: Conclusions
    Cardiovascular Safety Issues With COX-2 Specific Inhibitors
    Cardiovascular Safety Issues With COX-2 Specific Inhibitors (Continued)
    Cardiovascular Safety Issues With COX-2 Specific Inhibitors: Conclusions
    Cardiorenal Effects With Conventional Non-Steroidal Anti-inflammatory Drugs
    Cardiorenal Effects With COX-2 Specific Inhibitors
    Cardiorenal Effects With COX-2 Specific Inhibitors (Continued)
    Cardiorenal Effects With Newer COX-2 Specific Inhibitors
    Conclusions

  3. Pioneering Approaches in Orthopaedic Surgery: New Horizons in Bone Graft Substitutes
    Introduction
    Introduction to Bone Graft Properties
    Use of Bone Morphogenetic Proteins to Make Bone
    Effect of Pain Management on Healing
    The Species Specifics on Healing
    Assessing the Safety of Growth Factors
    Growth Differentiation Factor 5
    Use of Bone Morphogenetic Proteins: From Animal to Human Study
    Recombinant Bone Morphogenetic Proteins: Preclinical Study of Osteogenic Protein-1
    Clinical Study of Osteogenic Protein-1
    Recombinant Bone Morphogenetic Protein Type 2
    Preclinical Study of Recombinant Bone Morphogenetic Protein Type 2
    Additional Preclinical Work With Recombinant Bone Morphogenetic Protein Type 2
    From Animals to Humans With Recombinant Bone Morphogenetic Protein Type 2
    Using Gene Therapy to Make Bone
    LIM Mineralization Protein
    Proof of Concept: Using Gene Therapy to Make Bone and Fuse a Spine
    Using Virus to Get Genes Inside Cells
    Summary

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, the CME provider, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2002 Finch University of Health Sciences/The Chicago Medical School
Pfizer
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.